Jaroslaw Maciejewski, MD, PhD
Department Chair
Location: Cleveland Clinic Main Campus
Research
Dr. Maciejewski’s research deals with the molecular pathogenesis of leukemia genetics and bone marrow failure, with the focus on various specific aspects of stem cell biology, genetics, cytogenetics and immunobiology as well as targeted drug development.
Biography
Jaroslaw P. Maciejewski, MD, PhD, FACP, is Chair of the Department of Translational Hematology & Oncology Research and has an academic rank of Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is also Staff Physician in Cleveland Clinic's Department of Hematology & Medical Oncology and is board certified in hematology and internal medicine. In the Case Comprehensive Cancer Center, Dr. Maciejewski is Associate Director for Translational Research and a member of the Executive Committee. Read more about Dr. Maciejewski on his Cleveland Clinic clinical profile.
Education & Professional Highlights
Appointed
2001
Fellowship - National Heart, Lung and Blood Institute
Hematology
Bethesda, MD USA
2000
Residency - University of Nevada School of Medicine
Internal Medicine
Reno, NV USA
1998
Medical Education - Humboldt University Berlin, Medical School (Charite)
Immunology
Berlin,
1990
Medical Education - Humboldt University Berlin, Medical School (Charite)
Berlin,
1988
- Department Chair, Translational Hematology and Oncology Research
- Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
- Internal Medicine - Hematology
Bone marrow failure syndromes including aplastic anemia, myelodysplastic syndrome, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria, autoimmune neutropenia, pure red cell aplasia and other refractory anemias, cytopenias, acute lymphocytic leukemia
Awards & Honors- America's Best Doctors
- American Society of Clinical Investigation
- American Medical Association
- American Society of Hematology
- American Association of Physcians
- Member, Medical Advisory Board, Aplastic Anemia and MDS International Foundation
- Fellow in FACP since 7/1/09 from the Ohio Chapter 7/1/09
- American Society of Clinical Investigation
Research
Overview
Our group conducts translational investigations of the pathophysiology of bone marrow failure syndromes, including aplastic anemia, paroxysmal nocturnal hemoglobinuria, myelodysplastic syndromes, and related diseases. Aplastic anemia is a model of immune-mediated bone marrow failure syndromes and other immune cytopenias. Two aspects of this disease are the focus of our research: defective hematopoietic stem cell function, and its consequences and immune pathogenesis of stem-cell damage. Identification of expanded T-cell clones based on their unique TCR structure can also be applied to study anti-tumor immune surveillance such as that seen following allogeneic bone marrow transplantation in the form of the graft-versus-leukemia effect. We are also using similar principles to study clonal T-cell malignancies such as large granular lymphocyte leukemia, hairy cell leukemia, and T-cell lymphomas. Other ongoing studies include investigations of genetic predisposition and acquired chromosomal damage in myelodysplastic syndrome and acute myeloid leukemia using whole genome scanning approaches such as single nucleotide polymorphism arrays, methylation and expression arrays. These studies aim at development of novel molecular diagnostics and identification molecular targets for novel therapies.
Our Team
Selected Publications
View publications for Jaroslaw Maciejewski, MD, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Gurnari Carmelo, Durmaz Arda, Kewan Tariq, Pagliuca Simona, Visconte Valeria, Maciejewski Jaroslaw P. IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2023. 37053552.
Visconte Valeria, Crane Genevieve M, Durkin Lisa, Cook James R, Maciejewski Jaroslaw P, Rogers Heesun J. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms. Genes Chromosomes Cancer. 2023. 36959701.
Maciejewski Jaroslaw P. Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. Blood Adv. 2023. 36947201.
Gurnari Carmelo, Maciejewski Jaroslaw P. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023. 36940410.
Durmaz Arda, Gurnari Carmelo, Hershberger Courtney E, Pagliuca Simona, Daniels Noah, Awada Hussein, Mori Minako, Ponvilawan Ben, Kubota Yasuo, Kewan Tariq, Bahaj Waled S, Barnard John, Scott Jacob, Padgett Richard A, Maciejewski Jaroslaw P, Visconte Valeria. A multimodal analysis of genomic and RNA splicing features in myeloid malignancies. iScience. 2023. 36926651.
Kewan Tariq, Bahaj Waled, Durmaz Arda, Aly Mai, Ogbue Olisaemeka D, Carraway Hetty E, Visconte Valeria, Gurnari Carmelo, Maciejewski Jaroslaw P. Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood. 2023. 36720101.
Durmaz Arda, Gurnari Carmelo, Maciejewski Jaroslaw P. Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough? Br J Haematol. 2023. 36717968.
Gurnari Carmelo, Awada Hussein, Dima Danai, Maciejewski Jaroslaw P. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023. 36709353.
Gurnari Carmelo, Awada Hussein, Maciejewski Jaroslaw P. Hepatitis C Infection Associated with Acquired Pure Red Cell Aplasia. Trop Med Infect Dis. 2022. 36668915.
Pagliuca Simona, Gurnari Carmelo, Zhang Keman, Kewan Tariq, Bahaj Waled, Mori Minako, Nautiyal Ishani, Maciejewski Jaroslaw P, Wang Li, Visconte Valeria. Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. Int J Mol Sci. 2022. 36499220.
Zhao Ran, Maciejewski Jaroslaw. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials. Haematologica. 2023. 36325893.
Gurnari Carmelo, Maciejewski Jaroslaw P. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023. 36322930.
Kubota Yasuo, Zawit Misam, Durrani Jibran, Shen Wenyi, Bahaj Waled, Kewan Tariq, Ponvilawan Ben, Mori Minako, Gurnari Carmelo, LaFramboise Thomas, Visconte Valeria, Maciejewski Jaroslaw P. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022. 36266327.
Pagliuca Simona, Gurnari Carmelo, Terkawi Laila, Mori Minako, Visconte Valeria, Maciejewski Jaroslaw P. Molecular landscape of immune pressure and escape in aplastic anemia. Leukemia. 2023. 36253429.
Gurnari Carmelo, Mannion Peter, Pandit Ishani, Pagliuca Simona, Maciejewski Jaroslaw P, Visconte Valeria, Rogers Heesun J. Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia. Hemasphere. 2022. 36187875.
Radakovich Nathan, Mukerjee Sudipto, Shreve Jacob, Guan Yihong, Kuzmanovic Teodora, Hasipek Metis, Jha Babal, Maciejewski Jaroslaw P. A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. iScience. 2022. 36157589.
Maciejewski Jaroslaw P. Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis. Acta Haematol. 2023. 36108594.
Dima Danai, Jiang Dongxu, Singh Divya Jyoti, Hasipek Metis, Shah Haikoo S, Ullah Fauzia, Khouri Jack, Maciejewski Jaroslaw P, Jha Babal K. Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers (Basel). 2022. 36077618.
Maciejewski Jaroslaw P. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide. Blood Cancer J. 2022. 36071048.
Gurnari Carmelo, Pagliuca Simona, Patel Bhumika J, Durmaz Arda, Visconte Valeria, Maciejewski Jaroslaw P. Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. J Clin Oncol. 2023. 36054881.
Mehta Hrishikesh M, Penumutchu Srinivasa R, Tolbert Blanton S, Maciejewski Jaroslaw P, Corey Seth J. Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms. Leukemia. 2022. 35941213.
Kerr Cassandra, Maciejewski Jaroslaw. Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia. Leukemia. 2022. 35927326.
Maciejewski Jaroslaw P, Visconte Valeria. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov. 2022. 35926182.
Hong Sanghee, Rybicki Lisa, Gurnari Carmelo, Pagliuca Simona, Zhang Aiwen, Thomas Dawn, Visconte Valeria, Sobecks Ronald M, Kalaycio Matt, Gerds Aaron T, Carraway Hetty E, Mukherjee Sudipto, Advani Anjali S, Patel Bhumika J, Maciejewski Jaroslaw P. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2022. 35896698.
Kerr Cassandra M, Nagata Yasunobu, Maciejewski Jaroslaw P. Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. Blood Cancer Discov. 2022. 35839275.
Maciejewski Jaroslaw. Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans. Front Aging. 2022. 35821803.
Kongkiatkamon Sunisa, Terkawi Laila, Guan Yihong, Adema Vera, Hasipek Metis, Dombrovski Tatiana, Co Milo, Awada Hassan, Parker Yvonne, Pagliuca Simona, Gurnari Carmelo, Rogers Heesun J, Lindner Daniel J, Visconte Valeria, LaFramboise Thomas, Jha Babal K, Maciejewski Jaroslaw P. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia. 2022. 35761024.
Adema Vera, La Framboise Thomas, Radivoyevitch Tomas, Visconte Valeria, Sekeres Mikkael, Barnard John, Maciejewski Jaroslaw P. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q. EBioMedicine. 2022. 35617825.
Gurnari Carmelo, Maciejewski Jaroslaw P. Aplastic anemia: Quo vadis? Semin Hematol. 2022. 35491060.
Visconte Valeria, Maciejewski Jaroslaw P. Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia. Semin Hematol. 2022. 35491059.
Kerr Cassandra, Gurnari Carmelo, Maciejewski Jaroslaw P. Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8 T-cell large granular lymphocytic leukemia. Nat Commun. 2022. 35411050.
Hine Christopher, Yang Jie, Guan Yihong, Maciejewski Jaroslaw P, Jha Babal K. Sulfur Amino Acid Supplementation Abrogates Protective Effects of Caloric Restriction for Enhancing Bone Marrow Regrowth Following Ionizing Radiation. Nutrients. 2022. 35406143.
Woerner Jakob, Huang Yidi, Gurnari Carmelo, Wang Janet, Huang Yimin, Schnabel Daniel, Aaby Michael, Xu Wanying, Thorat Vedant, Jiang Dongxu, Jha Babal K, Koyuturk Mehmet, Maciejewski Jaroslaw P, LaFramboise Thomas. Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nat Commun. 2022. 35210415.
Gurnari Carmelo, Pagliuca Simona, Durmaz Arda, Zawit Misam, Maciejewski Jaroslaw P, Visconte Valeria. A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. Hematol Oncol. 2022. 35106810.
Maciejewski Jaroslaw. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia. 2022. 35091658.
Patel Bhumika, Singh Salendra, LaFramboise Thomas, Sekeres Mikkael A. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. J Clin Invest. 2022. 35085104.
Gurnari Carmelo, Maciejewski Jaroslaw P. Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. iScience. 2022. 35036869.
Kongkiatkamon Sunisa, Pagliuca Simona, Adema Vera, Nagata Yasunobu, Kerr Cassandra M, Awada Hassan, Gurnari Carmelo, Rogers Heesun J, Saunthararajah Yogen, Visconte Valeria, Maciejewski Jaroslaw P. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia. 2022. 34845315.
Gurnari Carmelo, Pagliuca Simona, Kewan Tariq, Bahaj Waled, Mori Minako, Patel Bhumika J, Visconte Valeria, Maciejewski Jaroslaw P. Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer J. 2021. 34839350.
Gurnari Carmelo, Pagliuca Simona, Guan Yihong, Hershberger Courtney E, Ni Ying, Awada Hassan, Kongkiatkamon Sunisa, Zawit Misam, Jha Babal K, Maciejewski Jaroslaw P, Visconte Valeria. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2022. 34768283.
Pagliuca Simona, Gurnari Carmelo, Awada Hassan, Kishtagari Ashwin, Kongkiatkamon Sunisa, Terkawi Laila, Zawit Misam, Guan Yihong, LaFramboise Thomas, Jha Babal K, Patel Bhumika J, Hamilton Betty K, Majhail Navneet S, Saunthararajah Yogen, Visconte Valeria, Chan Timothy A, Maciejewski Jaroslaw P. The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood. 2021. 34748628.
Gurnari Carmelo, Pagliuca Simona, Maciejewski Jaroslaw P. Pegcetacoplan versus Eculizumab in PNH. N Engl J Med. 2021. 34706184.
Dermawan Josephine K, Wensel Christine, Visconte Valeria, Maciejewski Jaroslaw P, Cook James R, Bosler David S. Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features. Am J Clin Pathol. 2022. 34661647.
Radakovich Nathan, Hilton C Beau, Shreve Jacob, Gerds Aaron T, Mukherjee Sudipto, Nagata Yasunobu, Jha Babal K, Maciejewski Jaroslaw P, Nazha Aziz. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Adv. 2021. 34592765.
Gurnari Carmelo, Yeaney Gabrielle A, Kalinowski Marcin, Cotta Claudiu V, Maciejewski Jaroslaw P. T-cell large granular lymphocytic leukemia associated with inclusion body myositis. Int J Lab Hematol. 2022. 34562064.
Zawit Misam, Gurnari Carmelo, Pagliuca Simona, Awada Hassan, Maciejewski Jaroslaw P, Saunthararajah Yogen. A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia. Clin Case Rep. 2021. 34552731.
Gurnari Carmelo, Colak Ceylan, Zawit Misam, Maciejewski Jaroslaw P. Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria. Lancet. 2021. 34509232.
Zawit Misam, Bahaj Waled, Gurnari Carmelo, Maciejewski Jaroslaw. Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. Cancers (Basel). 2021. 34503230.
Hershberger Courtney E, Daniels Noah J, Gurnari Carmelo, Padgett Richard A, Maciejewski Jaroslaw P. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021. 34473945.
Sekeres Mikkael A, Lucas George, Maciejewski Jaroslaw P. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022. 34448437.
Kubota Yasuo, Zawit Misam, Durrani Jibran, Shen Wenyi, Bahaj Waled, Kewan Tariq, Ponvilawan Ben, Mori Minako, Gurnari Carmelo, LaFramboise Thomas, Visconte Valeria, Maciejewski Jaroslaw P. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. 2022. 36266327.
Pagliuca Simona, Gurnari Carmelo, Terkawi Laila, Mori Minako, Visconte Valeria, Maciejewski Jaroslaw P. Molecular landscape of immune pressure and escape in aplastic anemia. 2022. 36253429.
Gurnari Carmelo, Mannion Peter, Pandit Ishani, Pagliuca Simona, Maciejewski Jaroslaw P, Visconte Valeria, Rogers Heesun J. Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia. 2022. 36187875.
Radakovich Nathan, Mukerjee Sudipto, Shreve Jacob, Guan Yihong, Kuzmanovic Teodora, Hasipek Metis, Jha Babal, Maciejewski Jaroslaw P. A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. 2022. 36157589.
Dima Danai, Jiang Dongxu, Singh Divya Jyoti, Hasipek Metis, Shah Haikoo S, Ullah Fauzia, Khouri Jack, Maciejewski Jaroslaw P, Jha Babal K. Multiple Myeloma Therapy: Emerging Trends and Challenges. 2022. 36077618.
Adema V, Palomo L, Toma A, Kosmider O, Fuster-Tormo F, Benito R, Salgado R, Such E, Larrayoz MJ, Xicoy B, Hernandez-Sanchez JM, Maietta P, Neef A, Fontenay M, Ibañez M, Diez-Campelo M, Alvarez S, Maciejewski JP, Fenaux P, Sole F. Distinct mutational pattern of myelodysplastic syndromes with and without 5q-treated with lenalidomide. Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16558.[Epub ahead of print] PubMed PMID: 32147816.
Gurnari C, Voso MT, Maciejewski JP, Visconte V. From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. Cancers (Basel). 2020 Feb 4;12(2). pii: E357. doi: 10.3390/cancers12020357. Review. PubMed PMID: 32033196; PubMed Central PMCID: PMC7072629.
Patel BJ, Barot SV, Kuzmanovic T, Kerr C, Przychodzen BP, Thota S, Lee S, Patel S, Radivoyevitch T, Lichtin A, Advani A, Kalaycio M, Sekeres MA, Carraway HE, Maciejewski JP. Distinctive and common features of moderate aplastic anaemia. Br J Haematol. 2020 Jan 31. doi: 10.1111/bjh.16460. [Epub ahead of print] PubMed PMID: 32004386.
Awada H, Mahfouz RZ, Durrani J, Kishtagari A, Jagadeesh D, Lichtin AE, Hill BT, Hamilton BK, Carraway HE, Nazha A, Majhail NS, Sobecks R, Visconte V, Kalaycio M, Sekeres MA, Maciejewski JP. Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. Br J Haematol. 2020 Apr;189(2):318-322. doi: 10.1111/bjh.16336. Epub 2020 Jan 20. PubMed PMID:31958160.
Patel BJ, Barot SV, Waldron M, Billings S, Vij A, Sekeres MA, Maciejewski JP, Carraway HE. Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. Leuk Lymphoma. 2020 May;61(5):1242-1245. doi: 10.1080/10428194.2019.1706734. Epub 2019 Dec 28. PubMed PMID: 31885297.
Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv.2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925. PubMed PMID: 31869410; PubMed Central PMCID: PMC6929388.
Durrani J, Maciejewski JP. Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):97-104. doi: 10.1182/hematology.2019000019. PubMed PMID: 31808900; PubMed Central PMCID: PMC6913491.
Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, Awada H, Asad MF, Kuzmanovic T, Suzuki H, Yoshizato T, Yoshida K, Chiba K, Tanaka H, Shiraishi Y, Miyano S, Mukherjee S, LaFramboise T, Nazha A, Sekeres MA, Radivoyevitch T, Haferlach T, Ogawa S, Maciejewski JP. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat Commun. 2019 Nov 26;10(1):5386. doi: 10.1038/s41467-019-13001-y. PubMed PMID: 31772163; PubMed Central PMCID: PMC6879617.
Nagata Y, Maciejewski JP. The functional mechanisms of mutations in myelodysplastic syndrome. Leukemia. 2019 Dec;33(12):2779-2794. doi: 10.1038/s41375-019-0617-3. Epub 2019 Oct 31. Review. PubMed PMID: 31673113.
Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00119. Epub 2019 Sep 20. PubMed PMID: 31663066; PubMed Central PMCID: PMC6818517.
Durrani J, Awada H, Kishtagari A, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel B, Nazha A, Lichtin A, Mukherjee S, Saunthararajah Y, Carraway H, Sekeres M, Maciejewski JP. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia. 2020 Mar;34(3):957-962. doi: 10.1038/s41375-019-0601-y. Epub 2019 Oct 17. PubMed PMID:31624375.
Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon S, Nagata Y, Patel BJ, Carraway HE, Sekeres MA, Maciejewski JP, Visconte V. Leukemia evolving from paroxysmal nocturnal hemoglobinuria. Leukemia. 2020 Jan;34(1):327-330. doi: 10.1038/s41375-019-0555-0. Epub 2019 Aug 20. PubMed PMID: 31431736.
Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP. Distinct clinical and biological implications of CUX1 in myeloid neoplasms. Blood Adv. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423. PubMed PMID: 31320321; PubMed Central PMCID: PMC6650742.
Kishtagari A, Jha BK, Maciejewski JP. TET2 mutations and clonal dynamics. Oncotarget. 2019 Mar 12;10(21):2010-2011. doi: 10.18632/oncotarget.26779. eCollection 2019 Mar 12. PubMed PMID: 31007843; PubMed Central PMCID: PMC6459340.
Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, Visconte V, Lichtin AE, Mustjoki S, Radivoyevitch T, Sekeres MA, Maciejewski JP. Subclonal STAT3 mutations solidify clonal dominance. Blood Adv. 2019 Mar 26;3(6):917-921. doi: 10.1182/bloodadvances.2018027862. PubMed PMID: 30898763; PubMed Central PMCID: PMC6436009.
Careers
Research News
The largest studies to-date on paroxysmal nocturnal hemoglobinuria provides information doctors need to determine the best treatment plans.
Data from thousands of patients with myeloid neoplasms reveals that PHF6 contributes to sex differences, poor prognosis in leukemia patients.
Drs. Jha and Maciejewski have identified eltrombopag as a potent inhibitor of specific leukemia cells, which could lead to new drugs that target leukemia cells while preserving and expanding normal blood cells.
Drs. Maciejewski and Jha developed a small molecule that selectively targeted and effectively eliminated cancer cells with a certain genetic mutation in preclinical models of myeloid leukemia, while simultaneously granting survival advantage to healthy cells.